Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non‐alcoholic fatty liver disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background/Aims: Primary biliary cirrhosis (PBC) is frequently associated with autoimmune diseases, including thyroid disease, although it is uncertain that this association is higher than in other liver diseases. Methods: We compared the prevalence and incidence of thyroid dysfunction (TD) in a series of patients with PBC (n=67) with patients with primary sclerosing cholangitis (PSC) (n=79) and non‐alcoholic fatty liver disease (NAFLD) (n=97) seen in a tertiary referral centre who had previously participated in clinical trials. Results: At initial evaluation, prevalence of TD in PBC was 13% compared with 11% in PSC (P=0.71) and 25% in NAFLD (P=0.08). Incidence of TD was 2.9 patients per 100 person‐years in PBC compared with 2.1 patients per 100 person‐years in PSC (P=0.57) and 1.8 patients per 100 person‐years in non‐alcoholic liver disease (P=0.45). Older age, female gender, biochemical abnormalities and concurrent autoimmune disorders were not predictive of the development of TD. Conclusions: TD was unexpectedly as common in patients with PBC as in patients with PSC and NAFLD, yet significantly more common than expected in the general population. Further investigation of thyroid disease in PSC and NAFLD is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727 · cited 1×
“08 17 (13, 23) 13 (7, 24) 11 (6, 20) 25 (17, 34)”
Self-citationUrsodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Self-citationThe presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504 · cited 2×
“Prevalence and incidence of TD among patients with PBC were significantly higher than the general population, consistent with previous published studies (4, 6, 7, 9).”
BackgroundResultUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · cited 2×
“As in previous studies, PBC was defined as chronic cholestatic liver disease for 4 6 months, positive antimitochondrial antibody, liver histology with features consistent with or diagnostic of PBC and the exclusion of other causes of liver disease (14).”
BackgroundMethodSelf-citationRisk factors for primary biliary cirrhosis in a cohort of patients from the United States
Parikh-Patel, A., Gold, E. B., Worman, H., Krivy, K. E., & Gershwin, E. M. (2001) · Hepatology · doi:10.1053/jhep.2001.21165 · Cited by 236
Insulin Action in Adipose Tissue and Muscle in Hypothyroidism
Dimitriadis, G., Mitrou, P., Lambadiari, V., Boutati, E., Maratou, E., Panagiotakos, D. B., Koukkou, E., Tzanela, M., Thalassinos, N., & Raptis, S. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0478 · Cited by 233
Cited by
Non-alcoholic fatty liver disease across the spectrum of hypothyroidism
Chung, G. E., Kim, D., Kim, W., Yim, J. Y., Park, M. J., Kim, Y. J., Yoon, J.-H., & Lee, H.-S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.027 · Cited by 305
Recent advances in clinical practice: Epidemiology of autoimmune liver diseases
Trivedi, P. J., & Hirschfield, G. M. (2021) · Gut · doi:10.1136/gutjnl-2020-322362 · Cited by 244
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Prevalence of hypothyroidism in nonalcoholic fatty liver disease
Pagadala, M. R., Zein, C. O., Dasarathy, S., Yerian, L. M., Lopez, R., & McCullough, A. J. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-2006-2 · Cited by 178
“Two previous studies with smaller sample sizes and incomplete histology reported prevalence rates of 15 and 20% for hypothyroidism in NAFLD [8, 15].”
BackgroundThyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses
Alonso-Merino, E., Martín Orozco, R., Ruíz-Llorente, L., Martínez-Iglesias, O. A., Velasco-Martín, J. P., Montero-Pedrazuela, A., Fanjul-Rodríguez, L., Contreras-Jurado, C., Regadera, J., & Aranda, A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506113113 · Cited by 108
Metadata
- Authors
- Silveira, M. G., Mendes, F. D., Diehl, N. N., Enders, F. T., & Lindor, K. D.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2009-07-02
- Volume
- 29
- Issue
- 7
- Pages
- 1094-1100
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2001564798
- Cited by
- 103
- References
- 8
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1111/j.1478-3231.2009.02003.x
- The paper
- Silveira, M. G., Mendes, F. D., Diehl, N. N., Enders, F. T., & Lindor, K. D. (2009). Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non‐alcoholic fatty liver disease. Liver International. https://doi.org/10.1111/j.1478-3231.2009.02003.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.